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Aim To investigate the relationship between plasma and 
cyst concentrations of albendazolesulphoxide (ASO) and 
their effects on parasitological findings and disease recur-
rence in patients with liver hydatidosis.
Methods The study was conducted at the University Hos-
pital for Infectious Diseases “Dr. Fran Mihaljević,” Zagreb, 
Croatia, between August 2006 and January 2011. Consec-
utive patients (N = 48, age 6-77 years) were treated with 
albendazole (3 × 5 mg/kg/d) over 28 days before surgical 
cyst removal (n = 34) or percutaneous evacuation (PAIR) 
(n = 14). Plasma ASO was determined on days 10 and 28 of 
treatment and cyst concentrations at surgery/PAIR. 
Results Disease recurred in 3 surgically treated patients. 
Variability of ASO concentrations was substantial. Plas-
ma concentrations on day 10 were higher than on day 
28 (geometric means ratio [GMR] 2.00; 95%CI 1.38-2.91, 
P < 0.001) and higher than cyst concentrations at the time 
of treatment (GMR = 1.58, 1.01-2.34, P = 0.045). Higher cyst 
(but not plasma) concentrations were independently asso-
ciated with lower odds of protoscolex motility (OR = 0.23, 
0.01-0.70, P < 0.001) and higher odds of protoscolex de-
struction (OR = 1.17, 1.04-1.46, P < 0.001). With adjustment 
for age and protoscolex motility, higher day 10 plasma 
concentrations (but not cyst concentrations) were asso-
ciated with lower odds of disease recurrence (OR = 0.49, 
0.09-0.97, P = 0.035). Plasma concentrations did not predict 
cyst concentrations.
Conclusion Viability of protoscolices progressively de-
creased with increasing ASO concentrations in the cyst. 
Data strongly suggested that higher plasma concentra-
tions reduced the risk of disease recurrence.
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Echinococcosis or hydatid cyst disease is an anthropozo-
onosis caused by the larvae of E. granulosus, E. multilocu-
laris, E. vogeli, and E. oligarthus (1). In transient hosts (eg, 
sheep, cattle, pigs, humans), the parasite develops in the 
form of hydatid cyst(s) of different sizes. The cyst consists 
of the outer layer (ectocyst), made of dense fibrous tissue; 
the middle layer (endocyst), which is elastic and lamellar 
in structure; and the inner (germinative) layer, which gives 
rise to buds that develop into scolices. The cyst content 
is hydatid fluid, produced by the germinative layer. In hu-
mans, the most commonly invaded organs are the liver and 
the lungs, but practically all organs can be affected (1-3). In 
Croatia, the disease is caused exclusively by E. granulosus. 
According to the European Hospital Morbidity Database 
(4) for the period 2010-2012, age-adjusted annual hospital 
admission rates due to echinococcosis (ICD-B67) in Croa-
tia varied between 0.011 and 0.0167/1000 population (ie, 
between 51 and 86 cases/y), indicating that the diseases is 
relatively rare but still stably present.
Treatments for hydatid cyst disease include surgical re-
moval of the cyst(s) (still most commonly used method); 
percutaneous aspiration of the cyst with instillation of a 
scolicidal agent (95% ethanol or hypertonic saline [15%-
20%] or albendazole), ie, the PAIR (puncture, aspiration, 
instillation, and re-aspiration) procedure, which seems 
to have greater clinical efficacy and lower rate of com-
plications than the surgical procedure; and treatment 
with benzimidazole anthelmintic drugs. The latter, phar-
macological option might be used as a monotreatment 
in the case of smaller cysts or when invasive approaches 
are not feasible, but it is typically adjunctive treatment 
to surgery or PAIR used to prevent dissemination of sco-
lices from ruptured cysts. In this setting, benzoimida-
zoles are used over at least 4 weeks before the definitive 
treatment (5-8). Among benzoimidazoles, albendazole 
is considered a cornerstone pharmacological treatment 
of echinococcosis. Although some controversies still ex-
ist regarding optimal dosing, the most widely accepted 
regimen implies administration of 10-15 mg/kg/d (5-8). 
Upon oral ingestion (with a fatty meal to increase bio-
availability), albendazole is rapidly metabolized (first-pass 
metabolism in the liver) into the active form albendazole-
sulphoxide (ASO), which inhibits tubuline polymerization 
in the parasite microtubules and inactivates cell division 
(9). Greater systemic bioavailability is considered an im-
portant advantage of albendazole over mebendazole, 
the other member of the group (9). Although ASO has 
been shown to penetrate both the hepatic and non-he-
patic cysts (9,10), the prognostic value of plasma and/or 
cyst concentrations has not been elucidated. Therefore, 
we aimed to relate ASO concentrations in the plasma and 
in the cysts, and to investigate their relationship with the 
parasitological and clinical outcomes in patients with liv-
er hydatidosis treated with albendazole over one month 
prior to surgical treatment or PAIR.
PATienTS AnD MeThoDS
General design and ethics
This prospective observational prognostic study was con-
ducted at a tertiary care university-affiliated teaching hos-
pital between August 2006 and January 2011 and was 
approved by the institutional Ethics Committee. The only 
procedures that differed from the standard treatment/fol-
low-up protocol were blood and cyst fluid samplings for 
determination of drug concentrations and laboratory eval-
uation of protoscolex viability.
Patients
Eligible for inclusion were consecutive patients (all ages) 
with standard (5,8) clinical and radiological (ultrasonogra-
phy [US] and computed tomography [CT]) criteria for liver 
echinococcosis with parasitologically proven disease (pro-
toscolices in the cyst content samples) who met the follow-
ing criteria: a) gave a written informed consent (guardians 
for children); and b) had a symptomatic or asymptomatic 
active echinococossis, ie, cyst types CL, CE1-CE3 accord-
ing to the World Health Organization (WHO) classification 
system (11). The WHO classification is based on US imag-
es: (i) CL – unilocular cyst lesion with uniform anechoic 
content, round or oval, cyst wall not visible; (ii) CE1 and 
CE2 – active cysts. CE1 is unilocular simple cyst, round or 
oval with a visible wall, typically showing fine echoes due 
to shifting of brood capsules (“snow flake sign”), whereas 
CE2 is multilocular with daughter cysts; (iii) CE3 – anecho-
ic cysts that are thought to be degenerating (transitional 
group). CE3a cysts feature the “water-lily” sign of floating 
membranes, whereas CE3b cysts are predominantly solid 
with daughter cysts; (iv) CE4 and CE5 are considered inac-
tive. They are echogenic with increasing degrees of cal-
cification and are nearly always nonviable. Patients with 
inactive disease (cyst types CE4 or CE5), patients with liv-
er cysts <30 mm in diameter, pregnant women, patients 
treated with ritonavir or phenytoin, and patients with an 
active malignant disease were not included. The com-
menced albendazole treatment was to be stopped 
in patients showing hypersensitivity reactions to 
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albendazole or developing other serious adverse events 
(particularly ≥5-fold increase in liver aminotransferases or 
granulocyte depletion to <0.5 × 103/mm3).
Study flow and procedures
Patients were hospitalized, routine biochemical/hema-
tological tests and serological tests were performed, and 
4-week treatment with albendazole was commenced (Fig-
ure 1). Albendazole (film-coated immediate-release tablets 
by Krka Pharmaceuticals (Novo Mesto, Slovenia) or Cilag-
Janssen (Beerse, Belgium) 15 mg/kg/d was divided in three 
daily administrations (at 06:00, 14:00, and 22:00 hours) with 
a meal consisting of 20 g of fatty cheese(45% milk fat). 
Doses were calculated weekly and rounded to the near-
est 100 mg. Routine biochemical/hematological tests were 
performed weekly and at the last day (day 28) of albenda-
zole treatment. Patients were daily evaluated for potential 
albendazole side-effects. Peripheral venous blood samples 
(3 mL) for determination of plasma ASO concentrations 
were collected into heparinized Vacutainer tubes on days 
10 and 28 of treatment at 09:00 hours, ie, at the time of 
the expected peak plasma concentration of ASO (3 hours 
after the first morning dose) (12). Plasma was separated 
and frozen at -72°C until assaying. Surgery or PAIR was per-
formed on the day of the last albendazole dose (within 8 
hours) (Figure 1). All surgeries (cystectomy or pericystec-
tomy) were performed at the Department of Surgery Uni-
versity Hospital Center Zagreb. All PAIR procedures were 
performed at the University Hospital for Infectious Diseas-
es “Fran Mihaljević,” Zagreb following the recommended 
WHO protocol (13) using 95% ethanol as a scolicidal agent. 
At surgery or PAIR, two samples of the cyst content were 
taken, one for parasitological evaluation and one (3 mL) for 
determination of ASO concentrations (frozen at -72°C un-
til assayed) (Figure 1). Regular follow-up visits were sched-
uled at 3, 9, and 24 months after completion of treatment 
(Figure 1), when physical examination, routine biochemi-
cal/hematological laboratory tests, and ultrasound exam-
ination were undertaken. CT of the abdomen was per-
formed in all patients at 9 and 24 months after treatment, 
and in those with suspected recurrence at 3 months after 
treatment. Chest CT was performed in all patients at the 
24-month visit. Disease recurrence was defined as any of 
the following: a) appearance of a cyst at the evacuation 
site; b) evidence of a new cyst at a different liver site; or c) 
evidence of a new cyst in any other organ.
Serodiagnostics
Sera were assessed for the presence of antibodies (IgG) 
against echinococcal antigens using a commercial semi-
quantitative enzyme-linked imunosorbent assay (ELISA) 
in line with the manufacturer’s instruction (the assay is 
based on purified hydatid liquid antigens [NovLisaTM, No-
vaTec GmbH, Leinfelden-Echterdingen, Germany]), and 
indirect fluorescence microscopy. For the latter analysis, 
after removal of fat using acetone, cryostat-madepro-
toscolex slices were incubated (37°C for 30 minutes) with 
diluted sera (1:100 in phosphate buffer pH 7.2), rinsed 
(3 × 10 minutes), incubated (37°C, 30 minutes) with anti-
human IgG antibodies labeled with fluorescin-izocyanate 
(Imunološki Zavod, Zagreb, Croatia), rinsed again, and an-
alyzed (14). A patient was considered seropositive when 
FiGuRe 1. Study flow. Procedures of primary relevance are indicted in bold. uS – ultrasound; CT – computed tomography; PAiR – 
percutaneous cyst evacuation (puncture, aspiration, instillation, re-aspiration).
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ELISA titers were ≥1:100 and fluorescence microscopy ti-
ters were ≥1:10.
Determination of albendazolesulphoxide 
concentrations
A validated high pressure liquid chromatography (HPLC) 
method with UV detection (wavelength 293 nm) devel-
oped by Hoaskey et al (15) and modified by Schipper et al 
(16) was used for determination of ASO concentrations in 
plasma and hydatid fluid. Briefly, after centrifugation (4000 
rpm, 10 minutes, 4°C), the sample was extracted by acidic 
denaturation over 30 minutes (400 μL of 3% HCl added to 
400 μmL of sample together with 20 mg/L of mebendazole 
hydroxide as internal standard) and supernatant separated 
by centrifugation at 14 000 rpm for 10 minutes. The HPLC 
parameters were as follows: Agilent 1200 system; 100 × 4.6 
mm (3 μm) CN spherisorb column; injection volume 100 
μL; flow rate 1.0 mL/min; mobile phase – 100 mmol ace-
tic acid buffer with 15% methanol, pH 3.5; elution time for 
the internal standard 11 minutes; elution time for ASO 8 
minutes. The lower limit of quantification (LLOQ) was 0.025 
mg/L, linear range (r >0.999) was 0.025-4.00 mg/L, and re-
covery at the low (0.025mg/L, LLOQ), medium (1.021mg/L), 
and high (3.890mg/L) part of the range was 83.0%, 96.0%, 
and 88.0%, respectively. Inter-day precision (coefficient of 
variation) was 4.71% and intra-day precision was 7.28%.
Parasitological evaluation
All evaluations were done by light microscopy at 37°C us-
ing unstained wet mount (17). Native specimens were first 
evaluated for the presence of protoscolices or their frag-
ments to confirm the diagnosis of echinococcosis. Further 
analysis aimed to estimate the level of protoscolex viability 
based on motility and morphological characteristics. Anal-
ysis of protoscolex-rich sediment obtained by centrifuga-
tion (17) was deemed non-discriminative since virtually 
no motility was observed in any of the samples. Hence, to 
re-create conditions resembling those in the canine gas-
trointestinal system, 1 mL of each sample was incubated 
with 0.05 mL of undiluted canine bile or 0.2% solution of 
sodium taurocholate in 1.0 mL of balanced Hank’s buffer 
pH 7.2 for 48 hours at 37°C and it was analyzed after 24 and 
48 hours of incubation (stimulation). Each sample was ana-
lyzed on at least 10 slides. Two outcomes were assessed: 
a) presence of any protoscolex showing motility (yes/no); 
b) proportion of observed protoscolices showing morpho-
logical signs of destruction(complete disintegration and 
free hooks, destruction of the tegmentum, loss off rostellar 
hook morphology, and loss of hooks) graded as “very good 
response” (>66%), “good response” (33%-66%), and “poor 
response” (<33%).
Research questions and data analysis
We posed three primary research questions. 1. Pharma-
cokinetic: what is the relationship between plasma and 
cyst concentrations? Analyses were performed by fitting 
general linear (mixed) models to ln(c) data and the ef-
fects were expressed as geometric means ratios, GMR 
[GMR = exp(ln(c
1) - ln(c2)] or regression coefficients (β). 
Within-subject variability of plasma concentrations (day 
10, day 28) was determined as relative standard deviation 
(%RSD = 100 x √es2wr–1) 2. Parasitological: do plasma and/or 
cyst ASO concentrations affect parasitological outcomes? 
Proportions of patients with motile protoscolices/patients 
with morphologically changed protoscolices were ana-
lyzed by fitting generalized linear models and results were 
expressed as odds ratios (OR). 3. Clinical outcome: are ASO 
concentrations related to disease recurrence? This relation-
ship was investigated by generalized linear models (effects 
expressed as OR). We used SAS 9.3 statistical software (SAS 
Inc., Cary, NC, USA) licensed to Zagreb University School 
of Medicine.
ReSulTS
Patient characteristics and description of outcomes
A total of 48 patients were enrolled, 34 (70.8%) submitted 
to surgery and 14 to PAIR as the final treatment. Diagno-
sis was confirmed parasitologically in all enrolled patients. 
Their characteristics are summarized in Table 1. No patient 
developed hypersensitivity to albendazole. No apparent 
trend in hematological/biochemical laboratory tests dur-
ing treatment was observed apart from normalization of 
the initially high erythrocyte sedimentation rate and C-
reactive protein values (not shown). Transient eosinophil-
ia was noted in 6 patients (12.5%) and elevations of liver 
enzymes, but not reaching the critical values, in anoth-
er 6. Hence, all 48 patients completed albendazole and 
final treatments and the 24-month follow-up. ASO con-
centrations in plasma were higher on day 10 than on day 
28 and than concentrations in the cyst (Figure 2A). The 
range of individual patient values was huge (25 to 80-
fold differences between minimum and maximum) (Fig-
ure 2A). Signs of protoscolex motility were observed in 
18/48 patients; ”good” morphological response (33%-
66% PS show signs of destruction) was observed 
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in 31/48 patients, and “good or very good” morphologi-
cal response (≥33% PS show signs of destruction) was ob-
served in 41/48 patients.
Relationship between ASo concentrations in plasma 
and the cyst
None of the factors depicted in Table 1 was associated 
with plasma or cyst ASO concentrations (not shown). Plas-
ma concentrations on day 10 were twice higher (P < 0.001) 
than on day 28 (Figure 3A) and around 53% higher than 
in the cyst (at surgery/PAIR) (P = 0.046) (Figure 3A). Within-
subject variability of plasma concentrations was very high 
(RSD = 105%). Plasma concentrations taken on day 28 were 
around 23% (but not significantly) lower than cyst concen-
trations (Figure 3A). Higher plasma concentrations on day 
10 were independently associated with higher concentra-
tions on day 28 (Figure 3B). They were, however, associated 
with lower cyst concentrations, albeit weakly (Figure 3C). 
No association between plasma ASO concentrations taken 
on day 28 and cyst concentrations was observed (Figure 
3D). There was no difference in plasma or cyst ASO con-
centrations between patients with fertile (CL, CE1, CE2, 
n = 35) and involutive (CE3, n = 13) cysts (not shown).
Relationship between plasma and cyst ASo 
concentrations and parasitological outcomes
For all patients, parasitological findings were identical after 
24 hours and after 48 hours of incubation with canine bile/
TABle 1. Patient characteristics*
Demographics:
age (years) 53.5 (6-77) 
(2 children 6 and 7 y)
men 21 (44.0)
epidemiological and clinical particulars:
positive epidemiological anamnesis 43 (89.6)
clinically symptomatic 28 (58.3)
first/recurrent episode 37 (77.1) / 11
serologically positive 31 (67.4)
US cyst classification: CL/CE1/CE2/CE3† 4 (8.3)/15 (32.3)/16 
(33.3)/13 (27.1)
fertile cyst (CL or CE1 or CE2) 35 (72.9)
laboratory (blood):
leukocytes ( × 109/L) 6.4 (3.5-13.7)
eosinophils (fraction) 0.020 (0-0.180)
erythrocyte sedimentation rate (mm/3.6 ks)15 (1-80)
C-reactive protein (mg/L) 2.5 (0.2-81.7)
aspartate aminotransferase (U/L) 22 (12-179)
alanineaminotransferase (U/L) 22 (9-481)
gama glutamyltransferase (U/L) 26 (7-281)
alkaline phosphatase (U/L) 69.5 (30-215)
Final treatment:
surgery/PAIR‡ 34 (70.8) 
(26 pericystectomy, 
8 cystectomy)/ 14
*Data are presented as median (range) or n (%).
†Who classification of the cysts based on ultrasound (uS) character-
istics (1). Types Cl, Ce1 and Ce2 are “fertile cysts,” whereas type Ce3 
shows signs of involution.
‡PAiR – percutaneous cyst evacuation (puncture, aspiration, instilla-
tion, re-aspiration).
FiGuRe 2. Study outcomes. (A) Pharmacokinetic outcomes: albendazolesulphoxide concentrations in plasma (days 10 and 28 of 
treatment) and in the cyst (obtained at surgery or PAiR). Shown are individual values (n = 48), medians, quartiles and inner fences 
(lower = 1st quartile – 1.5 × interquartile range; upper = 3rd quartile +1.5 × interquartile range). Values falling “out of the fences” are 
outliers. numerical values are median, minimum, and maximum. (B) Parasitological and clinical outcomes: number (%) of patients 
with signs of protoscolex (PS) motility or with different proportions of PS showing signs of destruction, and patients with disease 
recurrence. PAiR – percutaneous evacuation of the cyst (puncture, aspiration, instillation, re-aspiration).
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sodium taurocholate. Data for 48 hours are presented. Cyst 
ASO concentrations were strongly univariately associated 
with parasitological outcomes: 0.01 mg/L increase in con-
centration was associated with a 39% reduction in odds 
of finding signs of protoscolex motility (P < 0.001) (Figure 
4A) and with 14% increase in odds of having ≥33% pro-
toscolices with signs of destruction (“good or very good” 
morphological response) (P < 0.001) (Figure 4B). Cyst ASO 
concentrations ≥0.250mg/L were associated with ≤10% 
probability of finding motile protoscolices and with ≥90% 
probability of finding “good or very good” morphological 
response (Figure 4). Plasma ASO concentrations deter-
mined on day 10 showed a weak univariate association 
(P = 0.070) with protoscolex motility, which, however, was 
abolished with adjustment for cyst concentrations (not 
shown). No other trend of univariate association between 
plasma concentrations and parasitological outcomes was 
observed. None of the factors depicted in Table 1 showed 
even a trend (P < 0.250) toward univariate association with 
either parasitological outcome (not shown). With adjust-
ment for age, sex, “fertile cyst,” and obtaining of sample 
during surgery or PAIR, ASO cyst concentrations (by 0.01 
mg/L) were independently associated with lower odds of 
motile protoscolices (OR = 0.23, 95%CI 0.01-0.70, P < 0.001) 
and higher odds of “good or very good” morphological re-
sponse (OR = 1.17, 95% CI 1.04-1.46, P < 0.001).
Relationship between plasma and cyst ASo 
concentrations and disease recurrence
The three patients with disease recurrence were all wom-
en, treated surgically (2 pericystectomy, 1 cystectomy), 
all with previous (before the index) disease episodes and 
all tested seropositive at the start of the index treatment. 
Their characteristics were: case 1) age 66 years, CL (fertile) 
cyst, ASO plasma concentrations 0.149 and 0.132 mg/L on 
days 10 and 28, respectively, and cyst concentration 0.502 
mg/L. Parasitological findings indicated no signs of pro-
FiGuRe 3. Relationship between albendazolesulphoxide (ASo) concentrations in plasma and in the cyst. (A) Differences between 
ASo concentrations. Plasma and cyst ln(concentrations) were considered as repeated-measures data and were analyzed in a general 
linear mixed model accounting for autocorrelation and with adjustment for age, sex, and cyst classification (fertile [Cl or Ce1 or Ce2] 
vs Ce3). Differences are expressed as geometric means ratios (GMR) with 95% confidence interval (Ci). (B) Relationship between 
ln(plasma concentrations) on day 10 and day 28. Day 28 values were a dependent variable. Depicted is regression coefficient (β) with 
confidence intervals for day 10 concentrations as a predictor, adjusted for age, sex, and cyst classification (fertile vs Ce3). (C) Relation-
ship between day 10 ln(plasma concentrations) and ln(cyst concentrations). Cyst values were a dependent variable. Depicted is 
the adjusted (as above) effect (β) of day 10 concentrations. (D) Relationship between day 28 ln(plasma concentrations) and ln(cyst 
concentrations). Cyst values were a dependent variable. Depicted is the adjusted (as above) effect (β) of day 28 concentrations.
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toscolex motility and >66% protoscolices with signs of de-
struction; case 2) age 42 years, CE1 (fertile) cyst, ASO plas-
ma concentrations 0.290 and 0.188 mg/L on days 10 and 
28, respectively, and cyst concentration 0.222 mg/L. Parasi-
tological finding indicated protoscolex motility, and 33%-
66% protoscolices with signs of destruction; case 3) age 72 
years, CE3 (signs of involution) cyst, ASO plasma concen-
trations 0.188 and 0.042 mg/L on days 10 and 28, respec-
tively, and cyst concentration 0.155 mg/L. Parasitological 
findings indicated no signs of protoscolex motility and 
<33% protoscolices with signs of destruction. With adjust-
ment for age and presence of protoscolex motility, higher 
day 10 plasma ASO concentrations were associated with 
around 50% lower odds of disease recurrence considering 
all (P = 0.035) or only surgically treated patients (P = 0.041) 
(Table 2). Day 28 concentrations showed a trend toward 
univariate (Table 2), but not independent association (not 
shown), whereas cyst concentrations were unrelated to 
disease recurrence (Table 2).
DiSCuSSion
The present study emphasizes the importance of attain-
ing higher concentrations of the active albendazole me-
tabolite, ASO, in the hydatid cyst in order to achieve a more 
pronounced protoscolex inactivation in patients with liver 
hydatidosis. The study further suggests two important con-
clusions: a) that cyst concentrations might not be predict-
FiGuRe 4. univariate association between cyst albendazolesulphoxide concentrations and parasitological outcomes: (A) propor-
tion of patients with signs of protoscolex (PS) motility and (B) proportion of patients with ≥33% of PS showing signs of destruction 
(“good or very good” morphological response). estimated probabilities are from logit models with albendazolesulphoxide concentra-
tions in the cyst as the only independent variable. Depicted are odds ratios (oR) with 95% confidence intervals by 0.01 mg/l increase 
in drug concentration. Arrows indicate concentrations at which probabilities fall to ≤10% (A), ie, exceed 90% (B).
TABle 2. Association between albendazolesulphoxide (ASo) concentrations and disease recurrence*
All patients (n = 48) Surgically treated (n = 34)
odds ratio 
(95% confidence interval)
 
P-value
odds ratio 
(95% confidence interval)
 
P-value
univariate
ASO plasma, day 10 (by 0.1 mg/L) 0.58 (0.17-1.01) 0.061 0.62 (0.19-1.04) 0.084
ASO plasma, day 28 (by 0.1 mg/L) 0.47 (0.07-1.12) 0.113 0.52 (0.08-1.17) 0.147
ASO cyst (by 0.1 mg/L) 0.89 (0.47-1.33) 0.622 0.89 (0.47-1.33) 0.604
Multivariate†
ASO plasma, day 10 (by 0.1 mg/L) 0.49 (0.09-0.97) 0.035 0.50 (0.09-0.98) 0.041
Age (by 5 y) 1.61 (0.93-4.04) 0.102 1.89 (0.97-5.87) 0.065
No signs of protoscolex motility 0.35 (0.01-10.9) 0.500 0.26 (0.00-9.82) 0.442
*logit models were fit to proportion of patients with recurrence considering all patients and only those treated surgically (since all 3 cases were 
treated surgically). odds ratios are with profile-likelihood 95% confidence intervals and P-values are from likelihood-ratio tests.
†Plasma concentrations, age, signs of motility, protoscolex morphology, cyst type and previous disease episodes were entered into model and then 
successively removed if P > 0.500.
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able from the plasma concentrations; and b) that neither 
ASO concentrations in the cyst nor the level of protoscolex 
viability (at the end of a 4-week albendazole treatment) are 
predictive for a long-term clinical outcome. Rather, data 
suggest that higher plasma ASO concentrations (reflecting 
the tissue concentrations) are associated with a reduced 
risk or disease recurrence. Introduction of albendazole in 
treatment of hydatid cyst disease enabled a more liberal 
surgical approach and development of percutaneous cyst 
evacuation techniques by reducing the risks associated 
with spillage of the cyst content (5-8). Attempts are made 
to develop newer formulations allowing higher albenda-
zole’s bioavailability (12) and optimization of treatment 
regimens, although some controversies still exist (5-8). Re-
lationships between drug (ie, active metabolite, ASO) con-
centrations in plasma and the cyst and parasitological and 
clinical outcomes are important issues in this setting. The 
present study aimed to contribute to this matter.
The limited number of patients was due to a relatively low 
disease incidence and our intention not to exceed a 1.5-
year recruitment period in order to maintain consistency 
of study procedures. In this respect, and considering that 
the disease relapsed in only 3 patients during the study 
follow-up, the present observations relating higher plas-
ma ASO concentrations to a reduced risk of disease recur-
rence should be taken with caution. It should be noted, 
however, that our intention was not to detect “all possible 
factors” that might have influenced any of the analyzed 
outcomes, but to test the pre-defined hypotheses about 
ASO concentrations while accounting for (likely) the most 
relevant confounders. In line with this, the fact that we 
found no relationship between patient or disease charac-
teristics (eg, age, sex, seropositivity, symptomatic diseases, 
cyst type, pre-treatment laboratory findings) with plasma 
or cyst ASO concentrations, parasitological outcomes, or 
disease recurrence does not “disqualify” these factors as 
potentially relevant – the study was simply not designed 
to formally test their effects. At the same time, this did not 
compromise our observations. On the other hand, lack of 
drop-outs, high adherence to the procedures, the use of a 
validated method of ASO quantification, and a standard-
ized parasitological evaluation enabled a fair level of inter-
nal validity. Indirectly, present observations were externally 
validated by the fact that the observed ASO cyst concen-
trations were within the range of values reported in oth-
er studies with a similar dosing schedule, which, however, 
were conducted in considerably fewer patients (10,18,19). 
The fact that the study was conducted in a “regular prac-
tice” setting emphasizes its relevance.
With the limitation of being based on only two single-
point determinations (both at the expected time of peak 
concentrations, C
max, after the first morning dose), the ob-
servations related to plasma ASO concentrations were in 
agreement with the known high inter- and intra-subject 
variability. The fact that the values on day 10 of treatment 
were higher than on day 28 (end of treatment) could be 
due to several reasons. In a pharmacokinetic study in 
healthy volunteers (20), total exposure to ASO was re-
duced, elimination half-life shortened, and clearance was 
increased after 15 days of repeated dosing of albenda-
zole. Since volume of distribution was unchanged, data 
indicated time-dependent kinetics of ASO, likely due 
to induction of metabolizing enzymes (20). However, 
healthy volunteers do not have a hydatid cyst. Combined 
with the fact that Cmax in healthy participants was not af-
fected by repeated dosing (20), the presently observed 
higher ASO concentrations in the cyst determined within 
8 hours since the last dose than in plasma at the time of 
morning Cmax on day 28, suggest that the observed day 
10 to day 28 change could have also been due to a grad-
ual distribution of ASO into the cyst. Data clearly demon-
strate the importance of higher cyst concentrations for 
reduction of protoscolex viability. The lack of association 
between plasma concentrations and parasitological find-
ings is in line with the observed lack of their association 
with concentrations in the cyst. Still, present data strong-
ly suggest that higher plasma concentrations are asso-
ciated with a lower risk of disease recurrence. Although 
this observation might appear paradoxical (considering 
the lack of the effect on protoscolex viability), it seems 
pharmacodynamically plausible. The risk of disease recur-
rence after surgical cyst removal/PAIR is largely attribut-
ed to contamination due to the spillage of the cyst con-
tent. Clearly, the ability of shed protoscolices to generate 
a new cyst will depend on their viability. However, tissue 
ASO concentrations are also relevant since they could in-
hibit otherwise viable protoscolices. Animal studies show 
that ASO is readily distributed into different tissues where 
attained concentrations are comparable to plasma con-
centrations (eg, heart, lungs, spleen, colon) or are two 
(eg, kidney, small intestine) to four times higher (liver) 
(21). Once cyst has been removed, it appears reasonable 
to consider tissue ASO concentrations, reflected by the 
plasma concentrations, as an important factor in determi-
nation of the risk of disease recurrence. Our findings sup-
port the need for further studies investigating the rela-
tionship between more thoroughly evaluated systemic 
exposure to ASO (eg, repeated daily plasma concen-
tration-time profiles or cumulative total exposure 
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based on several daily concentrations) and disease recur-
rence as the primary clinical endpoint.
In conclusion, the present analysis in patients with liver 
hydatidosis treated with albendazole 15 mg/kg/d over 28 
days before surgery or PAIR demonstrates the importance 
of attaining higher ASO concentrations in the cyst for re-
duction of protoscolex viability. Cyst concentrations were 
not predictable from plasma concentrations determined 
at the expected morning Cmax on days 10 and 28 of treat-
ment. However, this does not exclude the possibility that a 
more detailed plasma concentration-time profiling would 
be predictive of the cyst ASO concentrations. At the same 
time, the study strongly suggests that higher plasma con-
centrations are associated with a lower risk of disease re-
currence.
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